Back to results
US 11,376,317 B2Granted
FcRn-targeted mucosal vaccination against RSV
AssigneeUniversity of Maryland, College Park
InventorsXiaoping Zhu, Weizhong Li
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversity of Maryland, College Park
InventorsXiaoping Zhu, Weizhong Li
Estimating the term…
Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn); a modified pre-fusion respiratory syncytia virus (RSV) F protein; and a trimerization domain. Disclosed are nucleic acid sequences capable of encoding peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn); a modified pre-fusion respiratory syncytia virus (RSV) F protein; and a trimerization domain. Also disclosed are methods for eliciting a protective immune response against RSV comprising administering to a subject an effective amount of a composition comprising a monomeric Fc fragment of an immunoglobulin recognized by FcRn; a modified pre-fusion RSV F protein; and a trimerization domain, wherein the administering is to a mucosal epithelium.
A peptide comprising
A method for eliciting a protective immune response against RSV comprising administering to a subject an effective amount of a composition comprising a fusion protein, wherein the fusion protein comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn, wherein the monomeric Fc fragment comprises an amino acid mutation that prevents dimer formation with other monomeric Fc fragments, wherein the monomeric Fc fragment of an immunoglobulin recognized by a FcRn comprises a mutation in the cysteine residues responsible for dimer formation;
A method of treating a subject exposed to RSV or at risk of being exposed to RSV comprising administering to the subject an effective amount of a composition comprising a fusion protein, wherein the fusion protein comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn, wherein the monomeric Fc fragment comprises an amino acid mutation that prevents dimer formation with other monomeric Fc fragments, wherein the monomeric Fc fragment of an immunoglobulin recognized by a FcRn comprises a mutation in the cysteine residues responsible for dimer formation;
Dependencies are inferred from the claim text.